Literature DB >> 19493541

Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met.

Efthimios Dardiotis1, Pantelitsa Koutsou, Eleni Zamba-Papanicolaou, Ilia Vonta, Marilena Hadjivassiliou, Georgios Hadjigeorgiou, Marios Cariolou, Kyproula Christodoulou, Theodoros Kyriakides.   

Abstract

BACKGROUND: Familial amyloidotic polyneuropathy (FAP) TTR Val30Met is a lethal autosomal dominant sensorimotor and autonomic neuropathy due to a substitution of methionine for valine at position 30 of the transthyretin (TTR) gene. Amyloid, composed of mutated TTR, is deposited in the peripheral nervous system, myocardium and kidneys. Considerable variability in the age of onset and penetrance of the disease occurs in different countries. Penetrance in Sweden, Cyprus and Portugal is 2%, 28% and 80% respectively. Environmental and genetic factors are believed to contribute to this variability. So far, no single modifier gene has been unequivocally associated with age of onset or penetrance.
METHODS: Candidate modifier genes were chosen from among those coding for chaperone proteins co-localized with TTR deposits in peripheral nerves. Seventy one TTRVal30Met carriers, 51 affected and 20 asymptomatic, belonging to 22 unrelated Greek-Cypriot families, and 59 normal controls were recruited for this study. Sequencing of the coding regions of TTR, serum amyloid P (APCS) and complement C1Q (A, B and C) genes was performed and APOE genotypes were determined. We searched for correlations between various polymorphisms of chaperone proteins and age of disease onset.
RESULTS: Four new and 4 previously described single nucleotide substitutions were identified. One polymorphic site in C1QA (rs172378) and one in C1QC (rs9434) as well as the epsilon2 allele correlated with age of onset (p<0.05).
CONCLUSIONS: Our study has identified polymorphisms which may influence the FAP-TTR Val30Met phenotype. Identifying modifier genes and their protein products may contribute to therapeutic advances.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19493541     DOI: 10.1016/j.jns.2009.05.018

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis.

Authors:  Andrea Iorio; Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Luca Pradotto; Alessandro Mauro; Anna Mazzeo; Claudia Stancanelli; Federico Perfetto; Sabrina Frusconi; Filomena My; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

2.  Association of C1q gene cluster variants with rheumatoid arthritis: a pilot study.

Authors:  Mariya Blagoeva Kosturkova; Galya Mihaylova Mihaylova; Tanya Kirilova Shivacheva; Maria Atanasova Radanova
Journal:  Rheumatol Int       Date:  2022-01-13       Impact factor: 2.631

3.  Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M).

Authors:  Diana Santos; Teresa Coelho; Miguel Alves-Ferreira; Jorge Sequeiros; Denisa Mendonça; Isabel Alonso; Carolina Lemos; Alda Sousa
Journal:  Eur J Hum Genet       Date:  2015-08-19       Impact factor: 4.246

4.  Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson's disease.

Authors:  Sophia Carbutt; Jennifer Duff; Alison Yarnall; David J Burn; Gavin Hudson
Journal:  Neurosci Lett       Date:  2015-03-26       Impact factor: 3.046

5.  Familial amyloid polyneuropathy in Portugal: New genes modulating age-at-onset.

Authors:  Diana Santos; Teresa Coelho; Miguel Alves-Ferreira; Jorge Sequeiros; Denisa Mendonça; Isabel Alonso; Carolina Lemos; Alda Sousa
Journal:  Ann Clin Transl Neurol       Date:  2016-12-20       Impact factor: 4.511

6.  Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy.

Authors:  E Panayiotou; R Papacharalambous; A Antoniou; G Christophides; L Papageorgiou; E Fella; S Malas; T Kyriakides
Journal:  Biochem Biophys Rep       Date:  2016-08-11

7.  Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy.

Authors:  Eleni Fella; Kleitos Sokratous; Revekka Papacharalambous; Kyriacos Kyriacou; Joy Phillips; Sam Sanderson; Elena Panayiotou; Theodoros Kyriakides
Journal:  Front Mol Neurosci       Date:  2017-05-10       Impact factor: 5.639

8.  C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.

Authors:  Elena Panayiotou; Eleni Fella; Revekka Papacharalambous; Stavros Malas; Maria Joao Saraiva; Theodoros Kyriakides
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

9.  C1QA and C1QC modify age-at-onset in familial amyloid polyneuropathy patients.

Authors:  Andreia Dias; Diana Santos; Teresa Coelho; Miguel Alves-Ferreira; Jorge Sequeiros; Isabel Alonso; Alda Sousa; Carolina Lemos
Journal:  Ann Clin Transl Neurol       Date:  2019-03-07       Impact factor: 4.511

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.